Compound ID | 3193
Ceftriaxone-sulbactam
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Synthetic; Small molecule; Direct acting; Indirect acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against extended-spectrum β-lactamase producing Escherichia coli (harbouring bla-CTX-M-15); indicated for infections of the urinary tract and respiratory tract |
| Description: | Drug combination; formulated for injection; cephalosporin-type beta-lactam |
| Institute where first reported: | Xiangbei Welman Pharmaceutical Co., Ltd |
| Year first mentioned: | 2007 |
| Highest development stage: | Phase 4 (NCT04066621) |
| Development status: | Active (as of 2024) |
| External links: | |
| Citation: | https://academic.oup.com/jac/article/60/1/187/729781?login=true |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.